Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler aerolizer®

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 5, 2012, Pages 265-279

  Jiang, Liqun ^a   Tang, Yue ^a   Zhang, Hongjiu ^a   Lu, Xifeng ^a   Chen, Xijing ^a   Zhu, Jiabi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Aerolizer ; Powder residence time; Respirable fraction

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

AEROSOL; ARTICLE; COMPUTATIONAL FLUID DYNAMICS; DISPERSION; DRUG FORMULATION; DRY POWDER; POWDER INHALER;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; HYDRODYNAMICS; INTERLEUKIN-2; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 84867052063     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0908     Document Type: Article

References (29)

1. Patton JS: Mechanism of macromolecule absorption by the lungs. Adv Drugs Deliv Rev. 1996;19:3-36.
2. Patton JS, Trinchero P, and Platz RM: Bioavailability of pulmonary delivered peptides and proteins: a-interferon, calcitonins and parathyroid hormones. J Control Release. 1994;28:79-85.
3. Zanen P, Go LT, and Lammers JWJ: The optimal particle size for parasympathicolytic aerosols in mild asthmatics. Int J Pharm. 1995;114:111-115.
4. Zanen P, Go LT, and Lammers JWJ: The optimal particle size for β-adrenergic aerosols in mild asthmatics. Int J Pharm. 1994;107:211-217.
5. Braun MA, Oschmann R, and Schmidt PC: Influence of excipients and storage humidity on the deposition of disodium cromoglycate. Int J Pharm. 1996;135:53-62.
6. Iida K, Hayakawa Y, Okamoto H, Danjo K, and Leuenberger H: Preparation of dry powder inhalation by surface treatment of lactose carrier particles. Chem Pharm Bull. 2003;51:1-5.
7. Iida K, Todo H, Okamoto H, Danjo K, and Leuenberger H: Preparation of dry powder inhalation with lactose carrier particles surface-coated using a Wurster fluidized bed. Chem Pharm Bull. 2005;53:431-434.
8. Jones MD, Harris H., Hooton JC, Shur J, King GS, Mathoulin CA, Nichol K, Smith TL, Dawson ML, Ferrie AR, and Price R: An investigation into the relationship between carrierbased dry powder inhalation performance and formulation cohesive-adhesive force balances. Eur J Pharm Biopharmacol. 2008;69:496-507.
9. Kumon M, Suzuki M, Kusai A, Yonemochi E, and Terada K: Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by IGC. Chem Pharm Bull. 2006;54:1508-1514.
10. Okamoto H, and Danjo K: Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv Drug Deliv Rev. 2008;60:433-446.
11. Chan HK: Dry powder aerosol drug delivery - opportunities for colloid and surface scientists. Colloids Surfaces A Eng Aspects. 2006;284-285.
12. Islam N, and Gladki E: Dry powder inhalers (DPIs) - a review of device reliability and innovation. Int J Pharm. 2008;360:1-11.
13. Prime D, Atkins PJ, Slater A, and Sumby B: Review of dry powder inhalers. Adv Drug Deliv Rev. 1997;26:51-58.
14. Voss A, and Finlay WH: Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm. 2002;248:39-50.
15. Coates MS, Fletcher DF, Chan HK, and Raper JA: Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length. J Pharm Sci. 2004;93:2863-2876.
16. Coates MS, Fletcher DF, Chan HK, and Raper JA: The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharmaceut Res. 2005;22:923-932.
17. Coates MS, Chan HK, Fletcher DF, and Raper JA: Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharmaceut Res. 2005;22:1445-1453.
18. Coates MS, Chan HK, Fletcher DF, and Raper JA: Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: air inlet size. J Pharm Sci. 2006;95:1382-1392.
19. Coates MS, Chan HK, Fletcher DF, and Chiou H: Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharmaceut Res. 2007;24:1450-1456.
20. Tang Y, and Zhu JB: Recombinant human interleukin-2 inhalation powders: preparation and distribution in the alveolus. Int J Pharm. 2008;360:225-227.
21. Tang Y, and Zhu JB: HPLC determination of recombinant human ineterleukin-2 (rhIL-2) in rhIL-2 powder for inhalation. Chin J Pharm Anal. 2005;25:1360-1363.
22. Borgström L, Olsson B, and Thorsson L: Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473-483.
23. DeHaan WH, and Finlay WH: Predicting extrathoracic deposition from dry powder inhalers. J Aerosol Sci. 2004;35: 309-331.
24. Grgic B, Finlay WH, Burnell PKP, and Heenen AF: In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries. J Aerosol Sci. 2004;35: 1025-1040.
25. Gotoh K, Masuda H, and Higashitani K: Powder Technology Handbook, 3rd ed. CRC/Tayler and Francis, Boca Raton, FL; p. 18, 2006.
26. Weiler C, Wolkenhauer M, Trunk M, and Langguth Peter: New model describing the total dispersion of dry powder agglomerates. Powder Technol. 2010;203:248-253.
27. Calvert G, Ghadiri M, and Tweedie R: Aerodynamic dispersion of cohesive powders: a review of understanding and technology. Adv Powder Technol. 2009;20:4-16.
28. Ooi J, Traini D, Hoe S, Wong W, and Young PM: Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. Int J Pharm. 2011;413:1-9.
29. Young PM, Edge S, Traini D, Jones MD, Price R, El-Sabawi D, Urry C, and Smith C: The influence of dose on the performance of dry powder inhalation systems. Int J Pharm. 2005;296:26-33.